The Kritzberger family’s farming legacy in the Red River Valley spans over a century. Originally venturing into livestock, they now focus on cultivating sugar beets, soybeans, and grains. The financial burden remains significant due to continued debt. ‘We’re in an incredible amount of debt,’ stated Ang Kritzberger during a farm walk in the fall.
For a decade, another challenge has loomed: their daughter Nina’s Type 1 diabetes. Diagnosed at age 7, Nina’s condition placed the family at the center of a nationwide discussion on insulin costs. ‘I slept by her bedside for the first 60 days,’ Ang recalled. ‘I had to check her blood sugar every two hours, nonstop.’
Annually, the Kritzbergers face over $8,000 in out-of-pocket medical expenses, despite possessing insurance. Rising insulin prices have previously forced many to ration doses, a risky endeavor. However, a movement to cap insulin expenses for diabetics is gaining momentum, supported by both Democrats and Republicans.
Sean Cleary, a Republican state senator from North Dakota, noted the bipartisan agreement: ‘Typically, Republicans favor the free market, while Democrats lean towards intervention. But here, consensus was reached due to a non-functioning market.’
Cleary co-sponsored legislation for a $25 monthly insulin price cap, aligning North Dakota with 29 other states. The cap shields patients from potentially exorbitant out-of-pocket costs, essential even with high deductibles.
Advocacy grew from stories of individuals unable to afford insulin despite dire need. Approximately 20% of the 40 million Americans with diabetes require insulin, a drug in use for over a century yet increasingly expensive. Federal data showed reduced out-of-pocket costs for privately insured patients, from $470 annually in 2018 to $220 in 2025. Families like the Kritzbergers find solace in potential protections against future price surges.
At 17, Nina Kritzberger balances health concerns with daily activities: ‘I need insulin, a spare pump, extra supplies,’ she listed. Insufficient doses risk hospitalization, exemplified by her statement, ‘Missing insulin could cause my body to fail.’
Initially, Democrats advocated for these caps; Colorado led in 2019 with a $100 limit on monthly insulin costs. In 2022, Medicare recipients saw a $35 monthly cap. Expansion efforts within private health insurance faced setbacks from Republican resistance.
North Dakota’s Sen. Tim Mathern championed similar state-level legislature for years, contending with minimal fellow Democratic support. State insurers claimed price relief for diabetics would elevate premiums for all.
Megan Hruby of Blue Cross Blue Shield of North Dakota argued, ‘Mandating coverage doesn’t reduce insurance costs.’
While many lawmakers remained wary, testimonies, including those from the Kritzbergers, influenced change. A demonstration of negligible effects on state employee insurance premiums helped sway opinions.
Janelle Moos from AARP noted, ‘Despite concerns on regulation overreach, legislators received confirmation of healthcare industry frustrations, particularly concerning high drug costs.’
In the vote for the insulin cap, bipartisan support was evident. The measure’s impact is limited due to its applicability to only certain state-regulated plans; larger employer health plans fall under federal jurisdiction. Public opinion reflects a shared desire for stronger drug price regulation.
As Congress contemplates a national insulin cap, Sen. Kevin Cramer, a North Dakota Republican, is among the supporters. Ang Kritzberger highlights a lesson from the discussion, emphasizing community unity: ‘In North Dakota, our strength lies in connections and common goals.’

Trump’s Cryptocurrency Ventures and Their Impact on Supporters
Amy Klobuchar’s Challenge as Minnesota Governor
The Purpose and Challenges of Signature Collection for Political Candidates in Illinois
Gray Wolves Stir Controversy Over Wildlife Management
Trump’s Push for Bipartisanship with Democrats